Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-03-31

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SNX-5422 to Treat Solid Tumor Cancers and Lymphomas

NCT00644072

Lymphoma Neoplasms

COMPLETED PHASE1

Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies

NCT00595686

Hematologic Neoplasms

COMPLETED PHASE1

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

NCT00506805

Cancer

COMPLETED PHASE1

Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies

NCT01635712

Cancer

COMPLETED PHASE1

Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers

NCT01848756

Cancer

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor Malignancy Lymphoid Malignancy (Lymphoma and CLL) Leukemia Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single Arm

Group Type EXPERIMENTAL

SNX-5422 Mesylate Hsp90 inhibitor

Intervention Type DRUG

dose escalated, tablets twice a week; undetermined duration until disease progression

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SNX-5422 Mesylate Hsp90 inhibitor

dose escalated, tablets twice a week; undetermined duration until disease progression

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Solid tumors or lymphoid malignancies refractory to standard therapy
* measurable disease
* recovery to Grade \< 1 toxicity due to prior adverse event or chemotherapy
* no chemotherapy within 4 weeks of entering study
* Age \> 18 years
* Karnofsy \>= 60%
* Life expectancy \> 3 months
* normal or adequate organ and marrow function

Exclusion Criteria

* receiving other investigational agents
* brain metastases
* uncontrolled medical illness
* HIV+ receiving combination antiretroviral therapy
* significant GI disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No